Related Experiment Video
Updated: Jun 14, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Effect of cetuximab treatment in squamous cell carcinomas
1Unit of Otolaryngology and Head & Neck Surgery, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. Marika.Nestor@bms.uu.se
Abstract:
The purpose of this study was to assess the effects of the monoclonal antibody cetuximab in a panel of cultured squamous cell carcinoma cell lines. This antibody, targeting the epidermal growth factor receptor (EGFR), is emerging as a promising agent for treatment of several cancers. As this antibody comes into clinical use, the identification of predictive markers of therapeutic benefit remains a pressing issue. Cells were first characterized according to EGFR expression, cell doubling time, and BRAF and K-ras mutations. The effects of cetuximab on cell-cycle distribution, proliferation, as well as cell growth rate were then evaluated. Cetuximab decreased cell proliferation in three out of four cell lines in a time-dependent manner, and all cell lines were found to exhibit wild type K-ras and BRAF genes. A possible correlation between EGFR expression and cetuximab effect on growth inhibition rate was observed, whereas reduction of cell doubling time seemed to be more dependent on initial growth rate. In addition, other factors may further influence the long-term treatment response of cetuximab. Moreover, the time-dependent manner of cetuximab response demonstrates the importance of long-term measurements for this substance.
Insights
Cetuximab, an antibody targeting epidermal growth factor receptor (EGFR), inhibited cancer cell proliferation in most tested cell lines. EGFR expression may correlate with cetuximab
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- The monoclonal antibody cetuximab targets the epidermal growth factor receptor (EGFR).
- Cetuximab is a promising therapeutic agent for various cancers.
- Identifying predictive markers for cetuximab efficacy is crucial for clinical application.
Purpose of the Study:
- To evaluate the effects of cetuximab on squamous cell carcinoma cell lines.
- To investigate potential predictive markers for cetuximab response.
- To understand the impact of cetuximab on cell proliferation and growth.
Main Methods:
- Characterization of cell lines based on EGFR expression, doubling time, and BRAF/K-ras mutations.
- Assessment of cetuximab's impact on cell-cycle distribution, proliferation, and growth rate.
- Evaluation of time-dependent effects of cetuximab treatment.
Main Results:
- Cetuximab reduced cell proliferation in three of four tested cell lines over time.
- All cell lines possessed wild-type BRAF and K-ras genes.
- A potential correlation between EGFR expression and growth inhibition was observed.
- Cell doubling time reduction appeared linked to initial growth rate.
Conclusions:
- Cetuximab demonstrates anti-proliferative effects in a subset of squamous cell carcinoma models.
- EGFR expression may serve as a predictive marker for cetuximab response.
- Initial growth rate influences the impact of cetuximab on cell doubling time.
- Long-term measurements are essential for fully assessing cetuximab's therapeutic potential.
